Research programme: Alzheimer's disease therapies - Transition Therapeutics
Alternative Names: AZD-102; Cyclohexanehexol isomers - Transition Therapeutics; Inositol isomers - Transition TherapeuticsLatest Information Update: 24 Aug 2010
Price :
$50 *
At a glance
- Originator Transition Therapeutics
- Class
- Mechanism of Action Amyloid beta-protein inhibitors; Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 20 Jul 2006 Preclinical trials in Alzheimer's disease in Canada (PO)
- 15 Mar 2006 Preclinical trials in Alzheimer's disease in Canada (unspecified route)